RxDoctor Payments Data

Ian Bledsoe, MD

Neurology · San Francisco, CANPI 1821228487

Payments from drug & device makers

$18,231in general payments, 2019–2025

Across 66 payments — averaging $276.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$5K
  • Ipsen Biopharmaceuticals, Inc$4K
  • AbbVie$3K
  • Amneal Pharmaceuticals LLC$2K
  • Boston Scientific$2K
  • Medtronic$2K
  • plus $1K from 2 others

What the payments were for

  • Consulting fees$13,09072%
  • Speaking & faculty fees$1,82610%
  • Travel & lodging$6444%
  • Food & beverage$2,67115%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen5$5,404
Ipsen Biopharmaceuticals, Inc1$3,650
AbbVie(2 entities)9$2,787
Amneal Pharmaceuticals LLC2$1,873
Boston Scientific17$1,565
Medtronic(2 entities)29$1,548
Acorda Therapeutics, Inc2$1,391
Neurocrine Biosciences, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,231 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$92,894
Medicare patients
208
Services billed
1,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa47$126,076
GocovriAmantadine Hcl15$24,459
Carbidopa-LevodopaCarbidopa/Levodopa360$17,199
NeuproRotigotine15$15,520
Carbidopa55$14,844
OngentysOpicapone12$7,912
AmantadineAmantadine Hcl105$7,339
Entacapone17$6,359
Tetrabenazine12$4,202
Carbidopa-Levodopa ErCarbidopa/Levodopa102$3,065
Mirtazapine56$1,769
Donepezil Hcl71$1,387
Clonazepam73$1,101
Quetiapine Fumarate27$1,065
Gabapentin15$1,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$1,873$126,07647 claims
Neurocrine Biosciences, Inc.Ongentys$13$7,91212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →